Tillotts Pharma

Executive Summary

Tillotts Pharma AG is a Swiss specialty pharmaceutical company wholly focused on gastroenterology. Founded in 1983 and headquartered in Rheinfelden, Switzerland, it operates as a subsidiary of the Japanese Zeria Group. Tillotts develops and markets proprietary and partnered products for inflammatory bowel diseases (IBD) such as ulcerative colitis and Crohn's disease, as well as other gastrointestinal disorders. With a product portfolio that includes Asacol, Pentasa, and other mesalazine-based formulations, the company has established a presence in over 65 countries through a combination of direct sales and licensing agreements. Tillotts' long-standing expertise in GI and its integration within the larger Zeria Group provide a stable foundation, though its private status limits visibility into specific financial performance and pipeline details. The company continues to focus on expanding its product reach and potentially developing new formulations to address unmet needs in IBD management.

Upcoming Catalysts (preview)

• 2027Potential FDA or EMA approval for a new IBD formulation (e.g., next-generation mesalazine or combination therapy)40% success
• 2026-2027Expansion of product availability into new geographic markets (e.g., China or Latin America)60% success
• TBDPositive topline results from a phase 3 trial for a novel GI candidate (if pipeline disclosed)30% success